MARKET

CRIS

CRIS

Curis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.460
0.000
0.00%
Closed 16:00 02/14 EST
OPEN
1.440
PREV CLOSE
1.460
HIGH
1.480
LOW
1.430
VOLUME
49.46K
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
0.9900
MARKET CAP
48.48M
P/E (TTM)
-1.6425
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRIS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRIS News

  • Curis and Aurigene Announce Amendment of Collaboration for the Development and Commercialization of CA-170
  • PR Newswire.02/06 13:30
  • Curis® and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies
  • PR Newswire.01/13 13:00
  • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • PR Newswire.01/08 21:31
  • Curis up 9% premarket on deal with ImmuNext in cancer
  • seekingalpha.01/07 18:59

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
-0.16%

Hot Stocks

Name
Price
%Change

About CRIS

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
More

Webull offers Curis, Inc. (CRIS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.